Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TroFuse 022/ENGOT ov84/GOG-3103 maintenance sacituzumab tirumotecan ± bevacizumab versus standard of care in platinum-sensitive recurrent ovarian cancer
2023-508015-23-00Phase 3Authorised
- Sponsor
- Merck & Co.
- Start
- Apr 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 29
01
Overview
Phase 3, randomised, open-label trial of sacituzumab tirumotecan in ovarian cancer, primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC) (3 arms), sponsored by Merck & Co. Primary endpoints: Part 1: Number of Participants with One or More Adverse Events (AE), Part 1: Number of Participants who Discontinue Study Intervention Due to an AE and 1 more. Planned start Apr 2025; status: authorised.
02
Drugs
sacituzumab tirumotecan
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on 2023-508015-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508015-23-00.